5/25/2010 3:34:10 PM
Executives from Heptares Therapeutics (Welwyn Garden City, UK) and O2h (Cambridge, UK)
announced today an extension of the agreement under which O2h provides multi-FTE -synthetic
chemistry services to support discovery programmes at Heptares.
Dr. Miles Congreve, Head of Chemistry said, “We are happy to have signed this new contract with O2h;
they have been a solid chemistry partner and have also supported us with some basic ADME, which
helps to reduce discovery cycle times.”
Sunil Shah, CEO, O2h “We have had a successful partnership with Heptares Therapeutics and are delighted
at this extension for the third year. Heptares has a very innovative technology that we are happy to have
supported since inception and believe will lead to new GPCR drugs being discovered.”
About Oxygen Healthcare Ltd
O2h is a 5 year old discovery services company co-located in Cambridge, UK and Ahmedabad, India.
The Indian operations provide a high level of chemistry expertise while UK office provides project
management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology
companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a
particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h
include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services labunits
and ADME. Further information on O2h can be found at www.o2h.com.
comments powered by